Do nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials?
This nomogram can be used to accurately predict a patient's risk for SDRT at the time of enrollment. Excluding patients at high risk for SDRT should improve the safety and efficiency of phase I trials.
Excess weight is more common than excessive alcohol consumption in the community and confers a greater risk of elevated aminotransaminase levels.